
Background: Individuals living with rheumatic disease who are marginalized by extreme poverty and housing instability suffer dramatically worse outcomes [1,2]. Those living in Vancouver’s Downtown Eastside experience high rates of substance use disorder, mental illness, and early mortality.[3] Since 2019, the Mary Pack Arthritis Program has operated a twice-monthly Rheumatology Clinic (“the Clinic”) in partnership with the Pender Community Health Centre, an inner-city primary care unit in Vancouver, Canada. Although this Clinic has lowered barriers to accessing care, challenges remain in adherence to follow-up appointments, monitoring labwork, and sustaining DMARD therapy.
Objectives: Our study aimed to first review the Clinic’s service provision and subsequently design and pilot an intervention to improve patient engagement in the care of their rheumatic disease.
Methods: We utilized a mixed-methods approach beginning with a retrospective chart review of all patients seen at the Clinic from January 2022 until June 2025. We concurrently conducted interviews with Clinic rheumatologists, inner-city primary care physicians, and patient representatives to understand specific barriers. Based on these findings, we designed a prospective trial for patients with inflammatory arthritis referred from local inner city community health centers. The intervention included a $20 honorarium for each follow-up visit they attended with completed bloodwork as well as a Rheumatology-specific outreach service that provided personalized education, advice, and appointment reminders. The primary outcome was the rate of attendance to follow-up visits in the study group compared to historical controls. The study was approved by the UBC REB (H24-03984).
Results: Between January 2022 and June 2025, the Clinic treated 167 unique patients (Table 1). The baseline rate of attendance to follow-up visits was 52.6% overall, and 42.4% among patients with a confirmed systemic autoimmune rheumatic disease. The patient population had high rates of comorbidity: 77% had substance use disorders, while 59% had mental health disorders. Housing instability was nearly universal; 12% of patients were unhoused, while 78% lived in modular, transitional, or single-room occupancy (SRO) housing. At a planned interim analysis of the prospective study (n=9), the rate of adherence to follow-up visits was significantly improved compared to historical controls (90.5% vs 42.4%, p < 0.001). For participants who were previously patients at the Clinic, follow-up rates improved compared to personal priors (87.5% vs 43.5%, p < 0.001). No concerning safety signals were identified.
Conclusions: Standard models of care are often insufficient for marginalized populations. An intervention combining modest financial incentives and specialized outreach support may improve adherence to follow-up in this cohort.
| Characteristic | n (%) or Mean (SD) |
|---|---|
| Total Patients | 167 |
| Sex | |
| Male | 85 (50.9%) |
| Female | 82 (49.1%) |
| Age (years ) | |
| Mean (SD) | 53.3 (12.5) |
| Housing Status | |
| Low barrier supportive housing | 75 (44.9%) |
| Single-room occupancy hotels | 40 (24.0%) |
| Unhoused | 22 (13.2%) |
| Modular or transitional housing | 15 (9.0%) |
| Market housing | 15 (9.0%) |
| Reason for Referral | |
| Possible systemic autoimmune rheumatic disease | 108 (64.7%) |
| Mechanical/soft tissue pain | 31 (18.6%) |
| Crystalline arthritis | 12 (7.2%) |
| Other | 16 (9.6%) |
| Comorbidities | |
| Substance use disorder* | 129 (77.2%) |
| Mental health disorder** | 99 (59.3%) |
| Appointment Adherence | |
| All Patients | |
| Total follow-ups made | 435 |
| Total follow-ups attended | 229 |
| Adherence Rate | 52.60% |
| Patients with Confirmed SARD*** | |
| SARD follow-ups made | 269 |
| SARD follow-ups attended | 114 |
| Adherence Rate | 42.40% |
*Defined as opioid use, stimulant use, or alcohol use disorder.
**Defined as depression, anxiety, bipolar disorder, schizophrenia and other chronic psychosis, or PTSD.
***SARD: Systemic Autoimmune Rheumatic Disease.
REFERENCES: [1] Rai B. Clin Rheumatol 2022; 41(6):1653-1657.
[2] Seta R. Clin Rheumatol 2020; 40(1):413-420.
[3] Vila-Rodriquez F. Am J Psychiatry 2013; 170(12):1413-1422.
Acknowledgments: NIL.
Disclosure of Interests: None declared.